Health Technology Assessment for Human Papillomavirus Vaccine

Running head: Healthcare
HEALTH TECHNOLOGY ASSESSMENT
By (Student's Name)
Class
Teacher
Name of the School
City
Date

Healthcare 2
Abstract
The paper appraised the Human Papillomavirus Vaccine as new health technology that
should be funded by the Australian ministry of health. The paper gives a vivid description of the
randomized double-blind placebo-controlled study to ascertain the effectiveness of the vaccine in
reducing cervical cancer infection among young women. The finding of the study shows a 90%
reduction of infection among 277 women on 95% CI against 257 placebo-controlled treated
women. The paper also gives an economic evaluation of the cost-effectiveness of adding the
HPV vaccine to the national cervical cancer screening program. The cost per LY is projected to
be $92 052 and the cost per QALY is $33 644 evidence in both boys and girls. Nature of clinical
evidence for safety, effectiveness, and efficacy of the HPV vaccine are also evaluated for a
conclusive discussion. The evaluation of economic cost-effectiveness of the vaccine, when used
based on the study conducted, is another area that the paper focused on. The paper concludes by
assessing the applicability of the HPV vaccine in the Australian context giving the possible
implication on the budget. The paper provides a recommendation that the vaccine should be
funded as it proves cost reduction due to reduced cost of treatment for cervical cancer.
Critical appraisal checklist
1. Random controlled trials

Healthcare 3

Healthcare 4